In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Effects of early statin treatment on acute heart failure and cardiovascular events after st-elevation myocardial infarction

Session Poster Session 3

Speaker Sergey Kozhukhov

Congress : EuroPrevent 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease - Other
  • Session type : Poster Session
  • FP Number : P602

Authors : S Kozhukhov (Kiev,UA), A Parkhomenko (Kiev,UA), A Shumakov (Kiev,UA), N Dovganych (Kiev,UA)

S Kozhukhov1 , A Parkhomenko1 , A Shumakov1 , N Dovganych1 , 1NSC “Institute of Cardiology” - Kiev - Ukraine ,

European Journal of Preventive Cardiology ( May 2018 ) 25 ( Supplement 1 ), 114

Background: We investigated whether early statin therapy could be beneficial to reduce acute heart failure (AHF) incidence in patients with ST-elevation myocardial infarction (STEMI) and improve survival during long term follow-up.

Methods: 307 STEMI patients were registered and followed-up prospectively, 128 of them (propensity score matching) were analyzed. 64 patients received any available statin in optimal doses within 6 hours of acute myocardial infarction (AMI) onset or no statin (n=64) and were followed up for 5 years. Reperfusion therapy was performed in 71.9%. The mean time from symptoms onset to hospital admission was 4.9±0.6 hours. We evaluated the effects of statin therapy on major adverse cardiovascular events, including AHF during in-hospital stay, cardiovascular death, non-fatal myocardial infarction and heart failure requiring hospitalization.

Results: Statin therapy significantly reduced the risk of the AHF incidence on the 3d day (p<0.05) and 7th day (p<0.01). We found a distinct loss of renal function of 4.4 ml/min in no-statin group and increase of glomerular filtration rate on 6.5 ml/min in statin group on the 10th day following AMI compare to 1st day (p<0.05 between groups). Statin therapy reduced the risk of cardiovascular death, non-fatal infarction and heart failure requiring hospitalization (p=0.014 by log rank).

Conclusions: The present study showed that early statin therapy in STEMI patients decreased incidence rate of AHF. Statin therapy markedly reduced the risk of the long-term mortality and subsequent cardiac events in AMI patients.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are